News uniQure N.V.

Equities

QURE

NL0010696654

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
5.04 ^USD	+5.00%		-0.40%	-25.55%

May. 08	Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating	MT
May. 07	UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating	May. 08	MT
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M	May. 07	MT
UniQure: Q1 Earnings Snapshot	May. 07	AQ
UniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress	May. 07	GL
Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director	Apr. 12	CI
UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating	Apr. 02	MT
UniQure N.V.(NasdaqGS:QURE) dropped from S&P Biotechnology Select Industry Index	Mar. 17	CI
Mizuho Securities Adjusts Price Target on uniQure to $7 From $10, Maintains Neutral Rating	Mar. 04	MT
Goldman Sachs Downgrades UniQure to Neutral From Buy, Cuts Price Target to $8 From $63	Feb. 29	MT
UniQure N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
UniQure Announces 2023 Financial Results and Highlights Recent Company Progress	Feb. 28	GL
RBC Cuts Price Target on UniQure to $28 From $33, Keeps Outperform Rating, Speculative Risk Qualifier	Jan. 03	MT
Kempen Downgrades UniQure to Neutral From Buy, Cuts Price Target to $18 From $28	Dec. 22	MT
Transcript : UniQure N.V. - Special Call	Dec. 19
Mizuho Downgrades uniQure to Neutral From Buy, Cuts Price Target to $10 From $52	Dec. 19	MT
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease	Dec. 19	GL
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease	Dec. 19	AQ
UniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease	Dec. 19	CI
UniQure N : December 2023 Huntington's Disease Program Update AMT-130	Dec. 19	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News uniQure N.V.

Equities

QURE

NL0010696654

Summary

Filters